Clinical evaluation of the Roche Elecsys CMV IgG Avidity assay
|
|
- Juliet Harrington
- 5 years ago
- Views:
Transcription
1 Eur J Clin Microbiol Infect Dis (2014) 33: DOI /s ARTICLE Clinical evaluation of the Roche Elecsys CMV IgG Avidity assay C. Vauloup-Fellous & T. Lazzarotto & M. G. Revello & L. Grangeot-Keros Received: 22 November 2013 /Accepted: 5 February 2014 /Published online: 2 March 2014 # The Author(s) This article is published with open access at Springerlink.com Abstract Congenital cytomegalovirus (CMV) infection has potentially severe consequences in newborns. The testing of pregnant women for CMV-specific antibodies may be useful for the identification of women at risk of transmitting the infection to the fetus. The determination of CMV IgG avidity helps to establish the timing of infection as IgG avidity matures during the course of infection. This study examines the performance of the Elecsys CMV IgG Avidity assay using preselected samples from patients at different phases of CMV infection. The Elecsys CMV IgG Avidity assay was tested at three sites using sequential samples from patients with recent primary CMV infection, as well as single samples from patients with recent primary or past CMV infection. The Elecsys assay discriminated well between early (low avidity) and late (high avidity) phases of infection in sequential serum samples. Overall, 98.8 % of low-avidity samples corresponded to infection onset <180 days before sampling and 77.8 % of all high-avidity results corresponded to infection onset >90 days before sampling. The assay s sensitivity was %, with specificity ranging from 89 to 100 %, C. Vauloup-Fellous UMR996, Univ Paris-Sud, Clamart, France C. Vauloup-Fellous AP-HP, Service de Virologie, Hôpital Paul Brousse, Villejuif, France T. Lazzarotto U.O. di Microbiologia, DIMES, Policlinico Universitario St. Orsola-Malpighi, University of Bologna, Bologna, Italy M. G. Revello Fondazione IRCCS Policlinico San Matteo, SC Ostetricia e Ginecologia, Pavia, Italy L. Grangeot-Keros (*) INSERM U764, Université Paris-Sud, AP-HP, Service de Virologie, Hôpital Paul Brousse, Villejuif, France liliane.keros@abc.aphp.fr depending on the consideration of gray-zone avidity values. Single samples from recent primary or past infection showed similar distributions of avidity results. The Elecsys CMV IgG Avidity assay results are in agreement with preselected samples from patients with primary or past CMV infection, showing that the test is an adequate predictor of the phase of infection. Introduction Congenital cytomegalovirus (CMV) infection has potentially severe consequences in the newborn, which include neurosensory hearing loss, mental retardation, impaired physical development, and, in some cases, neonatal death [1]. The highest risk of transmission of CMV from mother to fetus is associated with primary infection, and the risk of severe abnormalities is highest when primary maternal infection occurs in the periconceptional period or the first trimester of pregnancy [2 4]. This risk decreases throughout pregnancy, although the chance of CMV vertical transmission is greatest in the third trimester [3 5]. Maternal recurrent CMV infection (i.e., a reinfection with a new CMV strain or reactivation of a latent strain) can also result in congenital CMV [6]. However, only rarely do non-primary infections lead to severe clinical symptoms. The clinical diagnosis of maternal CMV infection is difficult, as symptoms are non-specific or absent in many cases. Hence, serological testing for CMV-specific immunoglobulin (Ig) M and IgG is required. IgM antibody is produced in the early phase of infection, and then declines in the following months, whereas IgG antibody levels increase gradually but can persist for several decades. This means that a subject who tests positive for CMV IgG only has been infected in the past. The scenario is much more complicated, however, if a subject tests positive for both IgM and IgG; in such a case, it is
2 1366 Eur J Clin Microbiol Infect Dis (2014) 33: impossible to discriminate primary infection from a nonprimary infection on a single serum sample [7]. Measuring the overall binding strength or avidity of CMV-specific IgG can help to make this distinction: primary infection generally will show low-avidity IgG in the early phases of infection, gradually maturing to high-avidity IgG approximately weeks after infection onset [8, 9]. Ideally, assays designed to measure CMV IgG avidity should detect virus-specific IgG of low avidity in serum samples taken early after the onset (i.e., in the first 2 3months) and IgG of high avidity in samples taken 6 or more months after infection onset, with IgG of moderate avidity detectable in between. However, a recent study showed that several currently available CMV IgG avidity assays do not achieve these ideal performance characteristics [10]. The aim of this study was to evaluate the recently developed Elecsys CMV IgG Avidity assay, which is unique in that it uses a mixture of viral recombinant proteins rather than whole CMV antigen. Materials and methods This study was carried out between March and July 2010 at three centers in Europe: Pavia, Italy; Bologna, Italy; and Paris- Clamart, France. Serum samples previously characterized at each of the centers were reanalyzed using the Elecsys CMV IgM, IgG, and IgG Avidity assays. Preselection of samples Frozen sequential serum samples taken from 61 pregnant women during routine clinical practice were reanalyzed at the center in Pavia (n=180 in total). In 52 (85 %) of these cases, the diagnosis had been made on the basis of IgG seroconversion in the presence (33 cases) or absence of clinical symptoms. The remaining nine cases (eight symptomatic) had been diagnosed by CMV IgM kinetics (ETI-CYTOK-M reverse assay; DiaSorin, Saluggia, Italy), CMV IgG avidity (in-house CMV IgG avidity ELISA [11]), and CMV DNAemia [12]. When possible, presumed dating of infection onset was based on the presence of clinical symptoms and/or abnormal laboratory findings. Otherwise, the date of onset was arbitrarily set between the last IgG-negative and first IgG-positive sample (median time lapse 42, range days). Single frozen serum samples from subjects with primary (n=100) and past CMV infections (n=50) were reanalyzed at the center in Bologna. Primary infection had been confirmed by clinical history as well as CMV IgM-positive and low CMV IgG avidity results, positive DNAemia, and/or demonstration of seroconversion for CMV-specific antibodies. Past infection had been determined by the absence of CMV IgM and high CMV IgG avidity results. Negative IgM results were confirmed with immunoblot testing [13]. In addition, 52 sequential serum samples from 16 patients with primary CMV infection were also included in the study. Seven out of 16 (44 %) patients with primary CMV infection had symptoms that could have been related to CMV infection in an immunocompetent subject (fever and/or an increase in hepatic transaminases). In this group, the onset of infection was based on the appearance of symptoms. In the remaining nine asymptomatic patients (56 %), the date of onset was estimated to be days (range, days) before the date of seroconversion (for IgM or IgG), as previously reported [9]. For preclassification, sera were tested using the Enzygnost CMV IgM assay and Enzygnost CMV IgG assay (Siemens Healthcare Diagnostics, Deerfield, IL, USA) and an in-house immunoblot for the detection of CMV-specific IgM [13]. CMV IgG avidity was tested with the Radim Cytomegalovirus IgG Avidity EIA WELL assay (Radim, Pomezia, Italy) [9]. The center in Paris-Clamart reanalyzed single frozen serum samples from pregnant women with primary (n=25) and past CMV infection (n=57), as well as 48 sequential frozen serum samples from 14 pregnant women with primary CMV infection. The sequential samples had been taken monthly during pregnancy and included first visit samples containing CMV IgM with or without low-avidity CMV IgG and respective follow-up samples. The onset of infection was estimated to be days before the first IgG-positive result. Samples had been preclassified using the Liaison CMV IgG and CMV IgM assays (DiaSorin, Saluggia, Italy). If CMV IgM and IgG were both present, IgG avidity measurement was performed. Low-avidity results obtained with the Liaison CMV IgG avidity assay (DiaSorin, Saluggia, Italy) were confirmed using an in-house ELISA and the VIDAS CMV IgG Avidity assay (biomérieux, Marcy-L Étoile, France). Elecsys CMV Avidity assay: principle, calculation, and interpretation of results The avidity assay consists of two measurements run in parallel using separate aliquots of the sample. The first is a reference measurement using undiluted sample or sample diluted as described above. In brief, the sample is incubated with a mixture of biotin- or ruthenium-labeled CMV-specific recombinant antigens to form sandwich complexes. Streptavidincoated paramagnetic microparticles are added, and complexes are attracted to the solid phase by streptavidin biotin interactions and a magnetic field. Unbound reagents are washed out of the system and bound antibody is detected by measuring voltage-induced chemiluminescence from the ruthenium labels. The second measurement follows the same reaction principle, but is performed in thepresenceofelecsys DilCMVAv buffer [0.8 M guanidine chloride, CMV-specific antigen (recombinant, E. coli); MES buffer 50 mmol/l,
3 Eur J Clin Microbiol Infect Dis (2014) 33: ph 6.5; preservative], which disrupts the binding of lowavidity IgG to CMV. Testing with the Elecsys CMV IgG Avidity assay is only applicable in samples that report a positive result with the Elecsys CMV IgG assay. If an IgG result >500 U/mL is obtained, the sample should be diluted 1:20 with Elecsys Diluent Universal prior to avidity determination. The reference and DilCMVAv-treated measurement results are used to manually calculate the ratio of high-avidity IgG present in the sample, as follows:. Avidity ð%aviþ ¼ DilCMVAv treatedmeasurement U ml. Referencemeasurement U ml 100 Samples reporting %Avi values <45.0 indicated lowavidity IgG and samples with %Avi 55.0 indicate highavidity IgG. Samples reporting %Avi ranging between 45.0 and 54.9 fall into the gray-zone and cannot be used to distinguish between past and active primary CMV infection. [14] Data analyses Results from the Elecsys CMV IgG avidity assay in sequential samples from patients with primary CMV infection were analyzed with respect to the percentage of samples that contained low-avidity, gray-zone, or high-avidity IgG within three time ranges: <90 days, days, and >180 days after the onset of infection/first bleed. Samples not tested due to insufficient sample volume and samples with negative or equivocal IgG results were excluded from the analysis. Single samples from patients with primary or past CMV infection from the Paris-Clamart and Bologna sites were presented as multidot plots to show the distribution of avidity results using the Elecsys CMV IgG Avidity assay from each site and by phase of infection. The sensitivity of the Elecsys CMV IgG Avidity assay was defined as the percentage of samples predefined as representing a primary CMV infection that gave low-avidity results, whereas the specificity was defined as the percentage of predefined samples from past CMV infection that gave high-avidity results. Results Sequential samples from patients with primary CMV infection In total, 246 sequential samples from patients with primary CMV infection from the three centers were included in the analysis. The distribution of CMV-specific IgG avidity results is shown in Fig. 1. Good discrimination between the early stages of infection (mainly low-avidity IgG results reported) and several months after infection (mainly high-avidity IgG results reported) was observed. There was some overlap in the distribution of the days time period samples: 49 % showed low avidity, 29 % were equivocal, and 22 % showed high avidity. The majority of the low-avidity results corresponded with infection onset <90 days prior to the sample being taken, with only 1.2 % corresponding to infection onset >180 days before sampling. Samples containing highavidity IgG corresponded to infection onset >90 days before sampling in 77.8 % of cases. Single samples from patients with primary or past CMV infection The distribution of CMV-specific IgG avidity results in single samples from patients with primary or past CMV infection from the centers in Paris-Clamart and Bologna is shown in Fig. 2. The distribution of avidity results from the two centers in both primary and past infection samples was very similar. A clear distinction between the types of infection was observed, with primary infection samples showing low-avidity IgG results and past infection samples showing high-avidity IgG results. Discrepant results were relevant to high avidity obtained in five samples collected from different cases of primary infection, and four low-avidity results were observed in the past infection group of samples. Two of these four samples were retested with a third avidity assay and gave high-avidity results. Assay sensitivity ranged from 91 to 97 % across the two testing centers (Table 1), and these values were very similar regardless of whether samples that fell into the gray-zone were excluded or were considered low-avidity samples. On the other hand, the specificity was slightly lower when samples with gray-zone avidity values were included in the lowavidity group (89.5 % in Paris-Clamart, 80.0 % in Bologna) than when they were excluded (100.0 % in Paris-Clamart, 90.9 % in Bologna; Table 2). Discussion In this study, the performance of the Elecsys CMV IgG Avidity assay was evaluated on two groups of previously characterized serum samples collected from subjects with primary or past CMV infection, respectively. The results appeared to correlate well with the sample classification. In pregnancy, the most important requirement for a CMV IgG avidity assay is to help in identifying or excluding a primary infection occurring in the previous 3 months in women presenting with a positive CMV IgM result. To reflect this, the sequential samples from all three centers were divided into three time points: <90 days, days, and >180 days after the onset of infection. The majority of samples taken <90 days
4 1368 Eur J Clin Microbiol Infect Dis (2014) 33: Table 1 Results from single samples from primary infection Paris-Clamart Bologna Samples tested a Low avidity Gray-zone 2 16 High avidity 2 3 Sensitivity b 91.30% 96.10% 95 % CI b Sensitivity c 92.00% 96.80% 95 % CI c a Seven samples excluded as they were IgG-negative with the Elecsys CMV IgG assay b Results falling within the gray-zone were excluded from the analysis Fig. 1 Distribution of CMV-specific IgG results from sequential samples at several time points after infection after infection onset were reported as containing low-avidity CMV IgG and the majority of samples taken >180 days after infection onset were reported as high-avidity CMV IgG by the Elecsys CMV IgG Avidity assay. A mixture of low-avidity, gray-zone, and high-avidity results (49 %, 29 %, and 22 % of samples, respectively) were observed in samples taken days after infection onset. The latter observation is consistent with the fact that the kinetics of the IgG avidity maturation process is likely to vary between individuals. Because of this, low-avidity IgG can be detected later than 90 days after c Results falling within the gray-zone were considered as low avidity for the analysis infection onset for some patients [8, 9], with a delay in IgG avidity maturation specifically observed in some pregnant women. This could explain why low-avidity results were reported for almost half of the samples taken days after infection onset in this study. Differences in the method used to ascertain the date of infection onset at the three sites in this study may also contribute to this variation. Using this assay, a primary infection would be identified with 95 % certainty, and a past infection would be identified with 92 % certainty. It should be noted that, in normal clinical practice, CMV IgG avidity measurements are only performed if patients also report a positive IgM result, so if the samples from this study taken >180 days after infection onset were the only samples that were tested for each of the patients, 15/24 samples would not actually have been assessed for CMV IgG avidity, as they were IgM negative. The single samples from patients with primary or past CMV infection were analyzed separately because it is much more difficult to accurately date the presumed onset of Table 2 Results from single samples from past infection Paris-Clamart Bologna Fig. 2 Distribution of CMV-specific IgG avidity results in single samples from patients with primary and past infections. *Three samples not shown due to avidity results >100 %. **Two samples not shown due to avidity results >100 % Samples tested Low avidity 0 4 Gray-zone 6 6 High avidity Specificity a % % 95 % CI a Specificity b 89.50% 80.00% 95 % CI b a Results falling within the gray-zone were excluded from the analysis b Results falling within the gray-zone were considered as low avidity for the analysis
5 Eur J Clin Microbiol Infect Dis (2014) 33: infection when only single samples are available. Overall, the Elecsys CMV IgG Avidity assay reported low-avidity IgG in 95 % of samples from primary infection and high-avidity IgG in 95 % of samples ( 85 % if equivocal results are considered low) from past infection. Data from other studies indicate that the results from CMV IgG avidity assays vary greatly. Differences have been observed in the ability of assays to correctly detect or exclude recent infection [15, 16] and in the results reported by different assays for the same samples. A comprehensive study by Revello et al. [10] using eight commercial CMV IgG avidity assays to test 198 samples found that none of the results were the same for all assays. Furthermore, the same qualitative result obtained with at least five assays was only reported for 59.6 % of the samples, highlighting the lack of standardization between the assays and the need to test sequential follow-up samples with the same assay. In addition, delayed IgG avidity maturation has been observed in pregnant women with CMV [2, 8, 9, 15] or toxoplasma [17] infections, thus potentially leading to misclassification of the actual phase of infection. Finally, changing the cutoff level may be necessary in order to improve performance, as recently reported for the VIDAS assay [18]. In conclusion, the results obtained using the Elecsys CMV IgG Avidity assay are in agreement with preselected samples classified as primary or past CMV infection. Therefore, the assay appears suitable for use in clinical practice. Acknowledgments The authors thank Tina Längin and her colleagues at Roche R&D, Penzberg, Germany for the protocol development, study coordination, and data analysis. Editorial support was supplied by Catriona Marshall, associated with Elements Communications Ltd., Westerham, UK and supported by Roche Diagnostics, Rotkreuz, Switzerland. Conflict of interest CV-F has received research funding from biomérieux and fees for consulting and attending meetings from Roche and DiaSorin. MGR, TL, and LG-K have received fees for lecturing from Roche. Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. Adler SP (2011) Screening for cytomegalovirus during pregnancy. Infect Dis Obstet Gynecol 2011: Revello MG, Gerna G (2008) Maternal, fetal and neonatal diagnosis of congenital human cytomegalovirus infection. Expert Opin Med Diagn 2: Enders G, Daiminger A, Bäder U, Exler S, Enders M (2011) Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 52: Picone O, Vauloup-Fellous C, Cordier AG, Guitton S, Senat MV, Fuchs F, Ayoubi JM, Grangeot Keros L, Benachi A (2013) A series of 238 cytomegalovirus primary infections during pregnancy: description and outcome. Prenat Diagn 33: Bodéus M, Hubinont C, Goubau P (1999) Increased risk of cytomegalovirus transmission in utero during late gestation. Obstet Gynecol 93: Wang C, Zhang X, Bialek S, Cannon MJ (2011) Attribution of congenital cytomegalovirus infection to primary versus nonprimary maternal infection. Clin Infect Dis 52:e11 e13 7. Munro SC, Hall B, Whybin LR, Leader L, Robertson P, Maine GT, Rawlinson WD (2005) Diagnosis of and screening for cytomegalovirus infection in pregnant women. J Clin Microbiol 43: Eggers M, Bäder U, Enders G (2000) Combination of microneutralization and avidity assays: improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy. J Med Virol 60: Lazzarotto T, Spezzacatena P, Pradelli P, Abate DA, Varani S, Landini MP (1997) Avidity of immunoglobulin G directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. Clin Diagn Lab Immunol 4: Revello MG, Genini E, Gorini G, Klersy C, Piralla A, Gerna G (2010) Comparative evaluation of eight commercial human cytomegalovirus IgG avidity assays. J Clin Virol 48: Revello MG, Gorini G, Gerna G (2004) Clinical evaluation of a chemiluminescence immunoassay for determination of immunoglobulin g avidity to human cytomegalovirus. Clin Diagn Lab Immunol 11: Furione M, Rognoni V, Cabano E, Baldanti F (2012) Kinetics of human cytomegalovirus (HCMV) DNAemia in transplanted patients expressed in international units as determined with the Abbott RealTime CMV assay and an in-house assay. J Clin Virol 55: Lazzarotto T, Ripalti A, Bergamini G, Battista MC, Spezzacatena P, Campanini F, Pradelli P, Varani S, Gabrielli L, Maine GT, Landini MP (1998) Development of a new cytomegalovirus (CMV) immunoglobulin M (IgM) immunoblot for detection of CMV-specific IgM. J Clin Microbiol 36: Elecsys CMV IgG Avidity assay package insert (2012) Roche Diagnostics GmbH, Mannheim, Germany 15. Lagrou K, Bodeus M, van Ranst M, Goubau P (2009) Evaluation of the new architect cytomegalovirus immunoglobulin M (IgM), IgG, and IgG avidity assays. J Clin Microbiol 47: Bodéus M, Beulné D, Goubau P (2001) Ability of three IgG-avidity assays to exclude recent cytomegalovirus infection. Eur J Clin Microbiol Infect Dis 20: Lefevre-Pettazzoni M, Le Cam S, Wallon M, Peyron F (2006) Delayed maturation of immunoglobulin G avidity: implication for the diagnosis of toxoplasmosis in pregnant women. Eur J Clin Microbiol Infect Dis 25: Vauloup-Fellous C, Berth M, Heskia F, Dugua J-M, Grangeot- Keros L (2013) Re-evaluation of the VIDAS( ) cytomegalovirus (CMV) IgG avidity assay: determination of new cut-off values based on the study of kinetics of CMV-IgG maturation. J Clin Virol 56:
Evaluation of the New Architect Cytomegalovirus Immunoglobulin M (IgM), IgG, and IgG Avidity Assays
JOURNAL OF CLINICAL MICROBIOLOGY, June 2009, p. 1695 1699 Vol. 47, No. 6 0095-1137/09/$08.00 0 doi:10.1128/jcm.02172-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Evaluation
More informationClinical Evaluation of a Chemiluminescence Immunoassay for Determination of Immunoglobulin G Avidity to Human Cytomegalovirus
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, July 2004, p. 801 805 Vol. 11, No. 4 1071-412X/04/$08.00 0 DOI: 10.1128/CDLI.11.4.801 805.2004 Copyright 2004, American Society for Microbiology. All Rights
More informationNew advances in the diagnosis of congenital cytomegalovirus infection
Journal of Clinical Virology 41 (2008) 192 197 New advances in the diagnosis of congenital cytomegalovirus infection Tiziana Lazzarotto a,, Brunella Guerra b, Marcello Lanari c, Liliana Gabrielli a, Maria
More informationEvaluation of the new ARCHITECT CMV IgM, IgG and IgG avidity assays
JCM Accepts, published online ahead of print on 1 April 0 J. Clin. Microbiol. doi:./jcm.01-0 Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationUpdate on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy
REVIEW 10.1111/j.1469-0691.2011.03564.x Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy T. Lazzarotto 1, B. Guerra 2, L. Gabrielli 1, M. Lanari 3 and M.
More informationon June 29, 2018 by guest
CVI Accepts, published online ahead of print on 27 August 2014 Clin. Vaccine Immunol. doi:10.1128/cvi.00487-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Role of Cytomegalovirus
More informationSerology and International units
Serology and International units L. Grangeot-Keros, National Reference Laboratory for Rubella, Virology Department, A. Béclère Hospital, Clamart, France Detection of rubella-specific IgG antibody Assays
More informationReliable screening for early diagnosis
Elecsys TORCH panel Reliable screening for early diagnosis Toxoplasmosis Rubella HSV CMV Toxoplasmosis The safe and sure approach to Toxo screening Ultrasensitive Toxo IgM optimized to detect all potential
More informationNational Prevalence Estimates for Cytomegalovirus IgM and IgG Avidity and Association between High IgM Antibody Titer and Low IgG Avidity
CLINICAL AND VACCINE IMMUNOLOGY, Nov. 2011, p. 1895 1899 Vol. 18, No. 11 1556-6811/11/$12.00 doi:10.1128/cvi.05228-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. National Prevalence
More informationCytomegalovirus IgG, IgM, IgG Avidity II Total automation for accurate staging of infection during pregnancy
Infectious Disease Cytomegalovirus IgG, IgM, IgG Avidity II Total automation for accurate staging of infection during pregnancy FOR OUTSIDE THE US AND CANADA ONLY Confidence in Your Results LIAISON Cytomegalovirus
More informationNon-commercial use only
Microbiologia Medica 2017; volume 32:6581 Evaluation of the TGS TA system for the detection of anti-cytomegalovirus antibodies Annalisa Cianflone, Maria Teresa Manco, Olivia Arpino, Alessia Paganini, Massimo
More informationNon-commercial use only
Microbiologia Medica 2017; volume 32:6583 Evaluation of the TGS TA system for the detection of anti-toxoplasma antibodies Olivia Arpino, Annalisa Cianflone, Maria Teresa Manco, Alessia Paganini, Massimo
More informationRelationship of IgG Avidity Index and IgM Levels for the Differential Diagnosis of Primary from Recurrent Cytomegalovirus Infections
ORIGINAL ARTICLE Iran J Allergy Asthma Immunol December 2007; 6(4): 197-201 Relationship of IgG Avidity Index and IgM Levels for the Differential Diagnosis of Primary from Recurrent Cytomegalovirus Infections
More informationCMV Infection and Pregnancy
Curr Obstet Gynecol Rep (2012) 1:216 222 DOI 10.1007/s13669-012-0028-1 HIGH-RISK GESTATION AND PRENATAL MEDICINE (T CHAN, SECTION EDITOR) CMV Infection and Pregnancy Yi-Ching Tung & Po-Liang Lu & Liang-Yin
More informationCytomegalovirus Immunity in Pregnancy in South of Iran
American Journal of Infectious Diseases 6 (1): 8-12, 2010 ISSN 1553-6203 2010 Science Publications Cytomegalovirus Immunity in Pregnancy in South of Iran 1 Abdolreza Sotoodeh Jahromi, 2 Mahin Jamshidi
More informationEpidemiology, prenatal diagnosis and maternal treatment
Societat Catalana d'obstetrícia i Ginecologia Curs de Formació Continuada 2015-2016 Del 10 de novembre de 2015 al 14 de juny de 2016 Sala 3 L'Acadèmia - Can Caralleu 15 de diciembre 2015 Epidemiology,
More informationInternational Journal of Biological & Medical Research
Int J Biol Med Res.2016;7(2):5495-5501 Int J Biol Med Res www.biomedscidirect.com Volume 6, Issue 2, April 2015 Contents lists available at BioMedSciDirect Publications International Journal of Biological
More informationHYPERIMMUNOGLOBULIN and CMV- DNAemia IN PREGNANT WOMEN WITH PRIMARY CYTOMEGALOVIRUS INFECTION
HYPERIMMUNOGLOBULIN and CMV- DNAemia IN PREGNANT WOMEN WITH PRIMARY CYTOMEGALOVIRUS INFECTION Giovanni Nigro, Rome, Italy Stuart P Adler, Richmond, VA, USA To avoid fetal rejection (50% allograft) an estrogeninduced
More informationDiagnosis and Management of Human Cytomegalovirus Infection in the Mother, Fetus, and Newborn Infant
CLINICAL MICROBIOLOGY REVIEWS, Oct. 2002, p. 680 715 Vol. 15, No. 4 0893-8512/02/$04.00 0 DOI: 10.1128/CMR.15.4.680 715.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Diagnosis
More informationA Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus
The new england journal of medicine original article A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Maria Grazia Revello, M.D., Tiziana Lazzarotto, Ph.D., Brunella Guerra,
More informationPrenatal diagnosis of congenital cytomegalovirus infection in 115 cases: a 5 years single center experience
DOI: 10.1002/pd.5025 ORIGINAL ARTICLE Prenatal diagnosis of congenital cytomegalovirus infection in 115 cases: a 5 years single center experience M. Enders 1 *, A. Daiminger 1, S. Exler 1, K. Ertan 2,
More informationDynamic relationship between infantile hepatitis syndrome and cytomegalovirus infection
EXPERIMENTAL AND THERAPEUTIC MEDICINE 13: 3443-3447, 2017 Dynamic relationship between infantile hepatitis syndrome and cytomegalovirus infection GUANGMENG WANG and DONGJIN FENG Department of Gastroenterology,
More informationDiagnosis of and Screening for Cytomegalovirus Infection in Pregnant Women
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2005, p. 4713 4718 Vol. 43, No. 9 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.9.4713 4718.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationImmune correlates of protection from congenital cytomegalovirus after primary infection in pregnancy
Laboratori Sperimentali di Ricerca, Fondazione IRCCS Policlinico San Matteo, Pavia, Italia Immune correlates of protection from congenital cytomegalovirus after primary infection in pregnancy Daniele Lilleri
More informationEvaluation of Four Commercial Systems for the Diagnosis of Epstein-Barr Virus Primary Infections
CLINICAL AND VACCINE IMMUNOLOGY, Mar. 2011, p. 444 448 Vol. 18, No. 3 1556-6811/11/$12.00 doi:10.1128/cvi.00486-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Evaluation of
More informationElecsys CMV IgG Avidity
07027095119 07027095500 English System information Short name Assay type To be used for CMVAVI cobas e flow samples with unknown Elecsys CMV IgG titer CMVAVI H cobas e flow samples with Elecsys CMV IgG
More informationParvovirus B19 Infection in Pregnancy
Parvovirus B19 Infection in Pregnancy Information Booklet Contents THE VIRUS page 3 CLINICAL MANIFESTATIONS page 6 DIAGNOSIS page 8 PATIENT MANAGEMENT page 10 REFERENCES page 12 Parvovirus B19 Infection
More informationBio-Rad Laboratories. The Best Protection Whoever You Are. Congenital and Pediatric Disease Testing
Bio-Rad Laboratories I N F E C T I O U S D I S E A S E T E S T I N G The Best Protection Whoever You Are Congenital and Pediatric Disease Testing Bio-Rad Laboratories I N F E C T I O U S D I S E A S E
More informationScreening for Cytomegalovirus Infection During Pregnancy in a Teaching Hospital, Western province, Sri Lanka
DOI: http://doi.org/10.4038/sljog.v39i4.7825 Screening for Cytomegalovirus Infection During Pregnancy in a Teaching Hospital, Western province, Sri Lanka Abeynayake J I a, Perera MAK b, Gunasekara C K
More informationThe Study of Congenital Infections. A/Prof. William Rawlinson Dr. Sian Munro
The Study of Congenital Infections A/Prof. William Rawlinson Dr. Sian Munro Current Studies SCIP Study of Cytomegalovirus (CMV) Infection in Pregnancy ASCI Amniotic Fluid Study of Congenital Infections
More informationPrediction of Congenital Cytomegalovirus Infection in High-Risk Pregnant Women
Clinical Infectious Diseases MAJOR ARTICLE Prediction of Congenital Cytomegalovirus Infection in High-Risk Pregnant Women Kenji Tanimura, 1 Shinya Tairaku, 1 Yasuhiko Ebina, 1 Ichiro Morioka, 2 Satoshi
More informationResearch Article Preconception Screening for Cytomegalovirus: An Effective Preventive Approach
BioMed Research International, Article ID 135416, 4 pages http://dx.doi.org/10.1155/2014/135416 Research Article Preconception Screening for Cytomegalovirus: An Effective Preventive Approach Orna Reichman,
More informationParvovirus B19 Infection in Pregnancy
Parvovirus B19 Infection in Pregnancy Information Booklet Contents The Virus page 3 Clinical Manifestations page 6 Diagnosis page 8 Patient Management page 10 References page 12 Parvovirus B19 Infection
More informationReceived 8 April 1996/Returned for modification 19 June 1996/Accepted 15 July 1996
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 1996, p. 2526 2530 Vol. 34, No. 10 0095-1137/96/$04.00 0 Copyright 1996, American Society for Microbiology Study of Abbott Toxo IMx System for Detection of Immunoglobulin
More informationUtility of Immunoblotting for Early Diagnosis of Toxoplasmosis Seroconversion in Pregnant Women
CLINICAL AND VACCINE IMMUNOLOGY, Nov. 2011, p. 1908 1912 Vol. 18, No. 11 1556-6811/11/$12.00 doi:10.1128/cvi.05303-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Utility of
More informationCongenital Cytomegalovirus Infection in the Absence of Maternal Cytomegalovirus-IgM Antibodies
Original Paper Received: September 16, 2016 Accepted after revision: January 5, 2017 Published online: March 4, 2017 Congenital Cytomegalovirus Infection in the Absence of Maternal Cytomegalovirus-IgM
More informationSee external label 2 C-8 C 96 tests Chemiluminescence. CMV IgM. Cat # Diluted samples, controls & calibrator 100 µl 30 minutes
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationWHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Murex HIV Ag/Ab Combination Number: PQDx
WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Murex HIV Ag/Ab Combination Number: PQDx 0144-043-00 Abstract Murex HIV Ag/Ab Combination with product codes 7G79-09 (GE41,
More informationCMV IgM. MODULAR ANALYTICS E170 cobas e 411 cobas e 602
04784618 190 100 English System information For cobas e 411 analyzer: test number 580 For MODULAR AALYTICS E170, cobas e 601 and cobas e 602 analyzers: Application Code umber 011 Intended use Immunoassay
More informationCYTOMEGALOVIRUS (CMV) IgM ELISA Kit Protocol
CYTOMEGALOVIRUS (CMV) IgM ELISA Kit Protocol (Cat. No.:EK-310-91) 330 Beach Road, Burlingame CA Tel: 650-558-8898 Fax: 650-558-1686 E-Mail: info@phoenixpeptide.com www.phoenixpeptide.com INTENDED USE The
More informationLecture-7- Hazem Al-Khafaji 2016
TOXOPLASMOSIS Lecture-7- Hazem Al-Khafaji 2016 TOXOPLASMOSIS It is a disease caused by Toxoplasma gondii which is a protozoan parasite that is infects a variety of mammals and birds throughout the world.
More informationHuman Cytomegalovirus IgM ELISA Kit
Human Cytomegalovirus IgM Catalog No: IRAPKT2012 ELISA Kit Lot No: SAMPLE INTENDED USE The CMV IgM ELISA is intended for use in the detection of IgM antibodies to Cytomegalovirus (CMV) infection in human
More informationComparison of the efficiency of two commercial kits ELFA and Western blot in estimating the phase of Toxoplasma gondii infection in pregnant women
Annals of Agricultural and Environmental Medicine 2016, Vol 23, No 4, 570 575 www.aaem.pl ORIGINAL ARTICLE Comparison of the efficiency of two commercial kits ELFA and Western blot in estimating the phase
More informationInnovation in Diagnostics. ToRCH. A complete line of kits for an accurate diagnosis INFECTIOUS ID DISEASES
Innovation in Diagnostics ToRCH A complete line of kits for an accurate diagnosis INFECTIOUS ID DISEASES EN TOXOPLASMOSIS Toxoplasmosis is a parasitic disease caused by with the obligate intracellular
More informationHuman Cytomegalovirus Virus (CMV) IgG ELISA Kit
Human Cytomegalovirus Virus Catalog No: IRAPKT1410 (CMV) IgG ELISA Kit Lot No: SAMPLE INTENDED USE The CMV IgG ELISA is intended for use in evaluating a patient s serologic status to cytomegalovirus (CMV)
More informationSee external label 2 C-8 C 96 tests CHEMILUMINESCENCE. CMV IgG. Cat # Step (20-25 C Room temp.) Volume
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationII.18. State of the Art and Trends in Cytomegalovirus Diagnostics. Maria Grazia Revello and Giuseppe Gerna
State of the Art and Trends in Cytomegalovirus Diagnostics II.18 Maria Grazia Revello and Giuseppe Gerna Abstract Diagnosis of human cytomegalovirus (HCMV) infection is required in two clinical situations:
More informationElecsys CMV IgG Avidity
05909708 119 100; equals to 50 CMV IgG avidity determinations English System information For cobas e 411 analyzer: test number 640 For MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers: Application
More informationLaboratory diagnosis of congenital infections
Laboratory diagnosis of congenital infections Laboratory diagnosis of HSV Direct staining Tzanck test Immunostaining HSV isolation Serology PCR Tzanck test Cell scrape from base of the lesion smear on
More informationPrognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood
DOI: 1.1111/j.1471-8.1.8.x www.bjog.org Fetal medicine Prognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood E Fabbri, a MG Revello, b M Furione, c M Zavattoni, c
More informationCLINICAL AUDIT SUMMARY CLINICAL AUDIT SUMMARY. Diagnosis and Recognition of Congenital Cytomegalovirus in Northern Ireland
Regional Virology Issue Date: 08/09/14 Page(s): Page 1 of 6 1.0 Name of audit Diagnosis and Recognition of Congenital Cytomegalovirus in Northern Ireland 2.0 Personnel involved Peter Coyle, Han Lu, Daryl
More informationElecsys CMV IgG cobas e 801. English System information
REF SYSTEM 07027117119 07027117500 300 cobas e 801 English System information Short name CMVIGG 10070 Please note ACN (application code number) The measured CMV IgG value of a patient s sample can vary
More informationToxoplasma gondii IgM ELISA Kit
Toxoplasma gondii IgM ELISA Kit Catalog Number KA0226 96 assays Version: 02 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationCongenital CMV infection. Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty, University of Sumatera Utara
Congenital CMV infection Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty, University of Sumatera Utara Congenital CMV infection Approximately 0.15 2% of live births
More informationVIDAS Test for Avidity of Toxoplasma-Specific Immunoglobulin G for Confirmatory Testing of Pregnant Women
JOURNAL OF CLINICAL MICROBIOLOGY, July 2002, p. 2504 2508 Vol. 40, No. 7 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.7.2504 2508.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationDevelopment of a New Cytomegalovirus (CMV) Immunoglobulin M (IgM) Immunoblot for Detection of CMV-Specific IgM
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1998, p. 3337 3341 Vol. 36, No. 11 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Development of a New Cytomegalovirus
More informationDIAGNOSTIC AUTOMATION, INC.
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationToxoplasma gondii IgM ELISA Kit
Toxoplasma gondii IgM ELISA Kit Catalog Number KA0226 96 assays Version: 01 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationElecsys CMV IgG. MODULAR ANALYTICS E170 cobas e 411 cobas e 601 cobas e 602
04784596 119 100 English System information For cobas e 411 analyzer: test number 570 For MODULAR ANALYTICS E170, cobas e 601 and cobas e 602 analyzers: Application Code Number 009 Please note The measured
More informationREAD HIGHLIGHTED CHANGES
BIO-FLASH Toxo IgM 3000-8554 50 tests The BIO-FLASH Toxo IgM is a fully automated chemiluminescent two-step immunoassay for qualitative measurement of IgM antibodies to Toxoplasma gondii in human serum
More informationCHEMILUMINESCENCE ENZYME IMMUNOASSAY (CLIA) Toxoplasma IgG. Cat # (20-25 C Room temp.) Volume
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationEffect of Testing for IgG Avidity in the Diagnosis of Toxoplasma gondii Infection in Pregnant Women: Experience in a US Reference Laboratory
1248 Effect of Testing for IgG Avidity in the Diagnosis of Toxoplasma gondii Infection in Pregnant Women: Experience in a US Reference Laboratory Oliver Liesenfeld, 1,2,3 Jose G. Montoya, 1,2 Sandra Kinney,
More informationKey words: birth defects, cytomegalovirus, day care, pregnancy
Research OBSTETRICS The frequency of pregnancy and exposure to cytomegalovirus infections among women with a young child in day care Beth C. Marshall, MD; Stuart P. Adler, MD OBJECTIVE: The purpose of
More informationTask Force Microbiology: Reimbursement Proposal Template (version 28/01/08) Cytomegalovirus opsporen van aviditeit van IgG antilichamen
04/2013 PROPOSAL: SUMMARY X NEW TEST O TEST WITHDRAWAL O CHANGE REIMBURSEMENT RULES OR PRICING Nederlandstalige omschrijving prestatie Cytomegalovirus opsporen van aviditeit van IgG antilichamen Diagnoseregel:
More informationCIC Edizioni Internazionali. Cytomegalovirus infection in pregnancy: review of the literature. Review
Cytomegalovirus infection in pregnancy: review of the literature Silvia Bonalumi 1, Angelica Trapanese 1, Angelo Santamaria 2, Laura D Emidio 3, Luisa Mobili 3 1 Department of Gynecology and Obstetrics,
More informationAcute parvovirus B19 infection frequently causes false positive results in the
CVI Accepts, published online ahead of print on 0 December 00 Clin. Vaccine Immunol. doi:0./cvi.000-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationPathogenesis and prenatal diagnosis of human cytomegalovirus infection
Journal of Clinical Virology 29 (2004) 71 83 Review Pathogenesis and prenatal diagnosis of human cytomegalovirus infection Maria Grazia Revello, Giuseppe Gerna Servizio di Virologia, IRCCS Policlinico
More informationTechnology makes many things possible, OBG. Tips on choosing the right tests and getting valid results. Signs of a hepatitis B carrier Page 49
OBG MANAGEMENT David A. Baker, MD Professor of Obstetrics, Gynecology, and Reproductive Medicine Director, Division of Infectious Diseases Health Sciences Center Stony Brook University Stony Brook, NY
More informationToxoplasma gondii IgM (Toxo IgM)
DIAGNOSTIC AUTOMATION, INC. 21250 Califa Street, Suite 102 and116, Woodland Hills, CA 91367 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com
More informationSeroconversion for Cytomegalovirus Infection During Pregnancy and Fetal Infection in a Highly Seropositive Population: The BraCHS Study
The Journal of Infectious Diseases BRIEF REPORT Seroconversion for Cytomegalovirus Infection During Pregnancy and Fetal Infection in a Highly Seropositive Population: The BraCHS Study Marisa M. Mussi-Pinhata,
More informationRubella virus IgG ELISA Kit
Rubella virus IgG ELISA Kit Catalog Number KA0223 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of
More informationDifferential kinetics of human cytomegalovirus load and antibody responses in primary infection of the immunocompetent and immunocompromised host
Journal of General Virology (), 9, 9 DOI.99/vir..7- Differential kinetics of human cytomegalovirus load and antibody responses in primary infection of the immunocompetent and immunocompromised host Giuseppe
More informationC M V a n d t h e N e o n a t e D r M e g P r a d o N e o n a t o l o g i s t D i r e c t o r, N I C U, S t F r a n c i s M e d i c a l C e n t e r
C M V a n d t h e N e o n a t e D r M e g P r a d o N e o n a t o l o g i s t D i r e c t o r, N I C U, S t F r a n c i s M e d i c a l C e n t e r C M V S e r o - P r e v a l e n c e ( I g G p o s i t
More informationReferences Required document for Laboratory Accreditation by the College of American Pathologists.
Subject NT-proBNP Cobas e601 Index Number Lab-4011 Section Laboratory Subsection Chemistry Category Departmental Contact Benjamin Michel Last Revised 10/19/2016 References Required document for Laboratory
More informationSeroprevalence of cytomegalovirus infection among pregnant women at Omdurman Maternity Hospital, Sudan.
Journal of Clinical Chemistry and Laboratory ISSN: xxxx-xxxx Vol. 1 (1), pp. 006-010, December, 2013. Global Science Research Journals Full Length Research Paper Seroprevalence of cytomegalovirus infection
More information1. Introduction. Correspondence should be addressed to Richard J. Drew; Received 23 July 2015; Accepted 15 November 2015
Infectious Diseases in Obstetrics and Gynecology Volume 2015, Article ID 218080, 5 pages http://dx.doi.org/10.1155/2015/218080 Research Article Pregnancy Outcomes of Mothers with Detectable CMV-Specific
More informationERA S JOURNAL OF MEDICAL RESEARCH CYTOMEGALOVIRUS INFECTION IN PREGNANCY- A REVIEW. Saeeda Wasim
REVIEW ARTICLE DOI:10.24041/ejmr2017.47 CYTOMEGALOVIRUS INFECTION IN PREGNANCY- A REVIEW Saeeda Wasim Department of Obstetrics and Gynecology Institute of Reproductive Medicine, HB-36/A/3, Sector-III,
More informationPrognostic Markers of Symptomatic Congenital Cytomegalovirus Infection
38 BJID 2008; 12 (February) Prognostic Markers of Symptomatic Congenital Cytomegalovirus Infection Roberta Maia de Castro Romanelli 1, Jean François Magny 2 and François Jacquemard 2 1 Clinical Hospital,
More informationImmunoglobulin M Toxoplasma Antibodies
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, JUlY 1994, p. 401-405 Vol. 1, No. 4 1071-412X/94/$04.00+0 Copyright C) 1994, American Society for Microbiology The Vitek Immunodiagnostic Assay for Detection
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 2, March 2014
PRELIMINARY EVALUATION OF CHORUS SYSTEM IN COMPARISON WITH COBAS 6000 SYSTEM FOR DETECTION OF ANTI-TOXOPLASMA-IGM ANTIBODIES BLERTA LAZE* ANILA MITRE** *Dept. of Biology, University Ismail Qemali, Vlora,
More informationCongenital Cytomegalovirus (CMV)
August 2011 Congenital Cytomegalovirus (CMV) Revision Dates Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive) August 2011 August 2011 June
More informationIgG Antibodies To Toxoplasma Gondii ELISA Kit Protocol
IgG Antibodies To Toxoplasma Gondii ELISA Kit Protocol (Cat. No.:EK-310-85) 330 Beach Road, Burlingame CA Tel: 650-558-8898 Fax: 650-558-1686 E-Mail: info@phoenixpeptide.com www.phoenixpeptide.com INTENDED
More informationScreening for Cytomegalovirus during Pregnancy
Virginia Commonwealth University VCU Scholars Compass Pediatrics Publications Dept. of Pediatrics 2011 Screening for Cytomegalovirus during Pregnancy Stuart P. Adler Virginia Commonwealth University, sadler@vcu.edu
More informationLIAISON Measles IgG The fully automated solution for quantitative antibody detection
LIAISON Measles IgG The fully automated solution for quantitative antibody detection FOR OUTSIDE THE US AND CANADA ONLY LIAISON Measles IgG Number of tests 100 Key assay features Method Assay range Solid
More informationCytomegalovirus Seroprevalence among Children 1-5 Years of Age in the United States: The National Health and Nutrition Examination Survey,
CVI Accepts, published online ahead of print on 17 December 2014 Clin. Vaccine Immunol. doi:10.1128/cvi.00697-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Cytomegalovirus
More informationWHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT. Product: Enzygnost HIV Integral 4 WHO reference number: PQDx
PQDx 0214-064-00 WHO PQDx PR April/2016, version 3.0 WHO Prequalification of In Vitro Diagnostics Programme PUBLIC REPORT Product: Enzygnost HIV Integral 4 WHO reference number: PQDx 0214-064-00 Enzygnost
More informationBIO-FLASH. BIOKIT, S.A. - Can Malé s/n Lliçà d Amunt - Barcelona - SPAIN
READ HIGHLIGHTED CHANGES BIO-FLASH anti-hbc 3000-8578 100 tests The BIO-FLASH anti-hbc is a fully automated chemiluminescent two-step immunoassay for qualitative measurement of total antibodies to hepatitis
More informationCriteria for the Use of CMV Seronegative Blood
Cx i Hc^jk^eui^xU j00$\ E. Dayan Sandler, MD Resident IV May 1988. Criteria for the Use of CMV Seronegative Blood Cytomegalovirus (CMV) is one of the herpes family of viruses with a very high worldwide
More informationVIDRL & WHO Measles IgM Proficiency Panel Final Report Prepared by Jennie Leydon, Michaela Riddell & Dr Mike Catton Director VIDRL
VIDRL & WHO Measles IgM Proficiency Panel 00702 Final Report Prepared by Jennie Leydon, Michaela Riddell & Dr Mike Catton Director VIDRL Table of Contents Tables and Figures... 3 Abbreviations... 4 Introduction...
More informationCEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE
CEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE TITLE : SOP for (off board dilution) Less Sensitive Modified VITROS Enzyme Immunoassay CEPHIA DOCUMENT
More informationMKT/BF/328
19.06.2013 MKT/BF/328 BIO-FLASH posters presented at ECCMID, 23rd Congress of Clinical Microbiology and Infectious Diseases Evaluation of HBV/HCV/HIV 1+2 Evaluation of TORC panel As you know this year
More informationReport of the WHO Collaborative Study to establish the First International Standard for Detection of IgG antibodies to Cytomegalovirus (anti-cmv IgG)
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017 Report of the WHO Collaborative Study to establish the First International Standard for Detection of IgG antibodies
More informationHSV Screening: Are Wesley Obstetricians Following the Guidelines? Dawn Boender, PGY4 Taylor Bertschy, PGY3
HSV Screening: Are Wesley Obstetricians Following the Guidelines? Dawn Boender, PGY4 Taylor Bertschy, PGY3 Goals To increase obstetrician knowledge regarding HSV screening Institute clinical changes at
More informationScreening Cytomegalovirus Infections in First Trimester of Gestation among High Prevalence Population
doi: 10.5505/actamedica.2016.53215 Acta Medica Anatolia Volume 4 Issue 3 2016 Screening Cytomegalovirus Infections in First Trimester of Gestation among High Prevalence Population Akın Usta 1, Mine Islimye
More informationModification and Evaluation of Avidity IgG Testing for Differentiating of Toxoplasma gondii Infection in Early Stage of Pregnancy
Original Article Modification and Evaluation of Avidity IgG Testing for Differentiating of Toxoplasma gondii Infection in Early Stage of Pregnancy Mohammad Reza Bonyadi, M.D. 1 *, Parvin Bastani, M.D.
More informationWHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere HIV Combo WHO reference number: PQDx
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: Alere HIV Combo WHO reference number: PQDx 0243-013-00 Alere HIV Combo with product codes 7D2842, 7D2843, 7D2843SET manufactured by Alere
More informationSignificance of a positive Toxoplasma Immunoglobulin M test result. in the United States
JCM Accepted Manuscript Posted Online 9 September 2015 J. Clin. Microbiol. doi:10.1128/jcm.01663-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 Significance of a positive
More informationSymptomatic congenital cytomegalovirus disease following non-primary maternal infection: a retrospective cohort study
Hadar et al. BMC Infectious Diseases (2017) 17:31 DOI 10.1186/s12879-016-2161-3 RESEARCH ARTICLE Symptomatic congenital cytomegalovirus disease following non-primary maternal infection: a retrospective
More informationELISA-VIDITEST anti-cmv IgG and IgG avidity
1023 ELISA-VIDITEST anti-cmv IgG and IgG avidity ODZ-177 96 Instruction manual PRODUCER: VIDIA spol. s r.o., Nad Safinou II 365, 252 42 Jesenice, Czech Republic, Tel.: +420 261 090 565, www.vidia.cz 1.
More information